&lt;p&gt;Mitochondria-Modulating Porous Se@SiO&lt;sub&gt;2&lt;/sub&gt; Nanoparticles Provide Resistance to Oxidative Injury in Airway Epithelial Cells: Implications for Acute Lung Injury&lt;/p&gt;

Wang, Muyun; Wang, Kun; Deng, Guoying; Liu, Xijian; Wu, Xiaodong; Hu, Haiyang; Zhang, Yanbei; Gao, Wei; Li, Qiang

doi:10.2147/ijn.s240301

Cited by 27 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…101 The strategies to tackle this problem include biogenic route of synthesis, conjugating peptides on metallic nanoparticles or immobilizing inorganic nanoparticles on silica nanoparticles. The main mechanisms of inorganic nanomedicine to treat ALI include inhibiting the inflammatory signal [37][38][39][40][41]44 and scavenging oxidants 36,42,43 (Table 4).…”

Section: Inorganic Nanomedicinementioning

confidence: 99%

“…1 h pre) Male C57BL/6 mice LPS (i.n.) Total cell↓, neutrophil↓, macrophage↑; IL-1β, CCL-2, IL-6↓; total protein, lung W/D ratio↓; H&E↑, score↓ [ 36 ] …”

Section: Different Nanomedicine Applications In Treating Alimentioning

confidence: 99%

“… 42 The nano-spheres could also modulate mitochondrial function, activity, and dynamics, signiﬁcantly increasing the epithelial cells’ resistance to oxidative injury. 36 …”

Section: Different Nanomedicine Applications In Treating Alimentioning

confidence: 99%

“…18 The above characteristics offer targets for site-specific delivery and the microenvironment for responsive drug release. To this end, the nanomedicine for ALI has broad alternative therapeutic strategies, including the delivery of anti-inflammatory agents to the disease site, [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] the direct scavenging of inflammatory factors, [35][36][37][38][39][40][41][42][43][44][45][46][47] the regulating of inflammatory cell activities, [48][49][50][51][52][53][54][55][56][57][58][59] or the modulating of inflammatory signaling pathways. [60][61][62][63][64][65]…”

Section: Introductionmentioning

confidence: 99%

“…[20][21][22]24,28,35,56,60,63 Nanomedicine can restore barrier integrity and prevent cell death by influencing inflammatory pathways 20,21,44,60,63,65,[70][71][72] and alleviating oxidative stress. 28,35,36,42,54,56 The influence of nanomedicine on cellular architecture can be assessed by a pragmatic optimized air-liquid interface system, which showed comparable results as those in an in vivo study. 90…”

mentioning

confidence: 99%

See 4 more Smart Citations

Nanomedicine-Based Therapeutics to Combat Acute Lung Injury

Bian¹,

Cai²,

Cui³

et al. 2021

IJN

View full text Add to dashboard Cite

Acute lung injury (ALI) or its aggravated stage acute respiratory distress syndrome (ARDS) may lead to a life-threatening form of respiratory failure, resulting in high mortality of up to 30-40% in most studies. Although there have been decades of research since ALI was first described in 1967, the clinical therapeutic alternatives for ALI are still in a state of limited availability. Supportive treatment and mechanical ventilation still have priority. Despite some preclinical studies demonstrating the benefit of pharmacological interventions, none of these has been proved completely effective to date. Recent advances in nanotechnology may shed new light on the pharmacotherapy of ALI. Nanomedicine possesses targeting and synergistic therapeutic capability, thus boosting pharmaceutical efficacy and mitigating the side effects. Currently, a variety of nanomedicine with diverse frameworks and functional groups have been elaborately developed, in accordance with their lung targeting ability and the pathophysiology of ALI. The in-depth review of the current literature reveals that liposomes, polymers, inorganic materials, cell membranes, platelets, and other nanomedicine approaches have conferred attractive therapeutic benefits for ALI treatment. In this review, we explore the recent progress in the study of the nanomedicinebased therapy of ALI, presenting various nanomedical approaches, drug choices, therapeutic strategies, and outcomes, thereby providing insight into the trends.

show abstract

Section: Inorganic Nanomedicinementioning

confidence: 99%

“…1 h pre) Male C57BL/6 mice LPS (i.n.) Total cell↓, neutrophil↓, macrophage↑; IL-1β, CCL-2, IL-6↓; total protein, lung W/D ratio↓; H&E↑, score↓ [ 36 ] …”

Section: Different Nanomedicine Applications In Treating Alimentioning

confidence: 99%

“… 42 The nano-spheres could also modulate mitochondrial function, activity, and dynamics, signiﬁcantly increasing the epithelial cells’ resistance to oxidative injury. 36 …”

Section: Different Nanomedicine Applications In Treating Alimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Nanomedicine-Based Therapeutics to Combat Acute Lung Injury

Bian¹,

Cai²,

Cui³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

Inflammation‐modulating nanoparticles for pneumonia therapy

Muhammad

Zhai

Wang

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Pneumonia is a common but serious infectious disease, and is the sixth leading cause for death. The foreign pathogens such as viruses, fungi, and bacteria establish an inflammation response after interaction with lung, leading to the filling of bronchioles and alveoli with fluids. Although the pharmacotherapies have shown their great effectiveness to combat pathogens, advanced methods are under developing to treat complicated cases such as virus‐infection and lung inflammation or acute lung injury (ALI). The inflammation modulation nanoparticles (NPs) can effectively suppress immune cells and inhibit inflammatory molecules in the lung site, and thereby alleviate pneumonia and ALI. In this review, the pathological inflammatory microenvironments in pneumonia, which are instructive for the design of biomaterials therapy, are summarized. The focus is then paid to the inflammation‐modulating NPs that modulate the inflammatory cells, cytokines and chemokines, and microenvironments of pneumonia for better therapeutic effects. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease

show abstract